IP Verse

Intas Pharmaceuticals competitive analysis

Loading summary...

Latest oppositions filed by Intas Pharmaceuticals

Explore patent oppositions filed by Intas Pharmaceuticals against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3529360
Methods For Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Protein ReductionNOVARTISJan 16, 2025
EP3270909
Fixed Dose Combinations Comprising Etc1002 And One Or More Statins For Treating Or Reducing Cardiovascular RiskESPERION THERAPEUTICSAug 1, 2024
EP2653162
Methods Of Administering Fluvoxamine TherapyINTERMUNEFeb 19, 2021
EP2506850
Methods Of Administering Pirfenidone TherapyINTERMUNEFeb 15, 2021
EP3246021
Apixaban FormulationsBRISTOL MYERS SQUIBB IRELANDAug 12, 2020
EP3251660
Apixaban FormulationsBRISTOL MYERS SQUIBB IRELANDJul 15, 2020
EP3257500
Apixaban FormulationsBRISTOL MYERS SQUIBB IRELANDJul 15, 2020
EP3017811
Apixaban FormulationsBRISTOL MYERS SQUIBBSep 4, 2019
EP3023095
Direct Compression Formulation And ProcessNOVARTISFeb 15, 2019
EP2956129
Pharmaceutical Compositions Containing Dexketoprofen And TramadolLABORATORIOS MENARINIJan 18, 2019

Latest patents of Intas Pharmaceuticals opposed by its competitors

Explore Intas Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3833335
Aug 31, 2022Pharmaceutical Composition Comprising Hmg-Coa Reductase Inhibitors And Fenofibrate2
EP2978426
Nov 13, 2019Stable Tigecycline Composition1
EP2917192
Mar 20, 2019Process For The Preparation Of Cabazitaxel And Its Intermediates1

Latest publications and patents of Intas Pharmaceuticals New

Explore the latest publications and patents granted to Intas Pharmaceuticals, showcasing their recent innovations and technological advancements.

Last updated on: Oct 20, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Intas Pharmaceuticals

EP3833335
Aug 31, 2022Pharmaceutical Composition Comprising Hmg-Coa Reductase Inhibitors And FenofibrateGranted And Under Opposition
EP2978426
Nov 13, 2019Stable Tigecycline CompositionGranted And Under Opposition
EP2917192
Mar 20, 2019Process For The Preparation Of Cabazitaxel And Its IntermediatesRevoked

Latest PTAB cases involving Intas Pharmaceuticals

Discover the latest PTAB cases involving Intas Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 26, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Intas Pharmaceuticals

IPR2025-00799Apr 3, 2025INTAS PHARMACEUTICALSATOSSA THERAPEUTICSPending
PGR2025-00043Apr 3, 2025INTAS PHARMACEUTICALSATOSSA THERAPEUTICSPending
PGR2023-00043Aug 18, 2023INTAS PHARMACEUTICALSATOSSA THERAPEUTICSFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Intas Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
INTAS PHARMACEUTICALS1643 -
BRISTOL MYERS SQUIBB IRELAND - 43 - -
BRISTOL MYERS SQUIBB IRELAND UNLIMITED - 43 - -
NOVARTIS6422 - 21